|Dose/Strength (ex. 1 mg or 1ml)||60mg/40mg|
|Usage||Clinical, Hospital, Personal|
Enoxaparin sodium is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. Other uses include inside kidney dialysis machines.
Common side effects include bleeding, fever, and swelling of the legs. Bleeding may be serious especially in those who are undergoing a spinal tap.Use during pregnancy appears to be safe for the baby. Enoxaparin is in the low molecular weight heparin family of medications.
Treatment of unstable angina (UA) and non-Q-wave myocardial infarction (NQMI), administered concurrently with aspirinDVT prophylaxis in knee replacement surgeryDVT prophylaxis in hip replacement surgery
DVT prophylaxis in abdominal surgery
Treatment of DVT with or without pulmonary embolism
Treatment of DVT inpatient, with ST-segment elevation myocardial infarction (STEMI)
Reversal agentProtamine sulfate is less effective at reversing enoxaparin compared to heparin, with a maximum neutralization of approximately 60% of the anti-factor Xa effect.
Enoxaparin is a FDA pregnancy category B drug which means enoxaparin is not expected to cause harm to an unborn baby when used during pregnancy.
The multiple-dose vials of the brand name enoxaparin (Lovenox) contain 15 mg benzyl alcohol per 1 mL as a preservative. Premature infants who have been given large amounts of benzyl alcohol (99 405 mg/kg/day) have experienced gasping syndrome.
Although enoxaparin is used to prevent blood clots it is necessary to remember that pregnancy alone can raise a woman's risk of clotting.
In people with unstable angina or non-Q-wave myocardial infarction:Atrial fibrillation, heart failure, lung edema, pneumonia: 0.5%v
Thrombocytopenia, i.e. can be associated with heparin-induced thrombocytopenia (0.5-5.0% of persons treated for at least five days)
Elevations in serum aminotransferases: 5.9%-6.1%
In people undergoing abdominal or colorectal surgery:Bleeding, anemia, ecchymosis: 2%
In persons undergoing hip or knee replacement:Fever, nausea, anemia, edema, peripheral edema: 2%
In persons with severely restricted mobility during acute illness:Dyspnea, thrombocytopenia, confusion, diarrhea, nausea: 2%
In people being treated for deep vein thrombosis:Injection site hemorrhage, injection site pain, hematuria: 2%
Mechanism of action
Enoxaparin binds to and potentiates antithrombin (a circulating anticoagulant) to form a complex that irreversibly inactivates clotting factor Xa. It has less activity against factor IIa (thrombin) compared to unfractionated heparin (UFH) due to its low molecular weight.PharmacokineticsAbsorption: Bioavailability (subcutaneous injection) ~ 100%
Distribution: Volume of distribution (anti-Factor Xa activity) = 4.3 liters
Metabolism: Enoxaparin is metabolized in the liver into low molecular weight species by either or both desulfation and depolymerization.
Elimination: A single dose of a subcutaneous injection of enoxaparin has an elimination half-life of 4.5 hours. Approximately 10 40% of the active and inactive fragments from a single dose are excreted by the kidneys. Dose adjustments based on kidney function are necessary in persons with reduced kidney function.
- Packaging Details: 60MG/40MG